Stuck with stiff joints? This 5-move kettlebell trainer workout is your range-of-motion reset
If your hips feel tighter than your work schedule, you're not alone. Hours spent sitting at a desk, commuting, or even just lounging on the sofa can leave your hips stiff, your lower back grumbling, and your movement feeling anything but nimble.
To help loosen things up and strengthen the muscles around your hips, personal trainer Shaina Fata has created a five-move mobility routine using a kettlebell. If you're in the market for equipment, we've tested the best kettlebells for home workouts.
Fata's routine is designed to improve lower body joint health and build functional strength using just one weight and a jump box. If you don't have a box, try a sturdy step, low bench, or even a wide staircase.
There are no quick fixes when it comes to improving mobility and strength. Things like building range of motion take time and consistency. But this routine is a great place to start, especially if you're feeling stiff and want to move with more freedom.
Watch trainer Shaina Fata's mobility and strength routine for the hips
What are the benefits
This five-move routine may look simple on paper, but each exercise is carefully chosen to target common trouble spots like tight hips, stiff joints, and underused glutes. It includes moves like kettlebell windmills and halos which will challenge your balance and coordination while opening up the shoulders and hips.
You'll also tune into some deep squats and kneeling hip shifts that will encourage mobility in the lower body. Meanwhile the high box step-ups add a dose of functional strength which the benefits will carry over into everyday movement.
These exercises are most effective when done with proper form, and slowing down each move can help you focus on control rather than rushing through the reps.
If you are new to mobility work or kettlebell training, it's worth taking a moment to watch trainer Fata's demonstrations closely. These exercises are most effective when done with proper form, and slowing down each move can help you focus on control rather than rushing through the reps. Pay attention to how Fata moves with intention throughout the routine. This kind of focus is key to building strength and improving range of motion over time.
The kettlebell is not just there to add weight. Adding load challenges your stability, activates deeper muscle engagement, and helps you build strength through a greater range of motion. It can also improve posture, increase core strength, and encourage better joint control.
Quick note: this routine may not be suitable for everyone. Deep squats and weighted mobility work can feel too intense for beginners or anyone dealing with pain or injury. If that sounds familiar, try one of our picks of bodyweight mobility routines or explore lower-impact strength workouts to build a foundation first.
More from Tom's Guide
This mobility test takes just seconds — and it could predict how well you'll age
Hate sit-ups? Study shows this is the only activity you need to strengthen your core
Want to protect your brain as you age? Science says to start with this routine
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Saquon Barkley says he's not a member of President Trump's Council on Sports Nutrition
In a move that will revive a standard from the Reagan, Clinton, and Bush era, Harrison Butker, Nick Bosa, Tony Romo, and Lawrence Taylor will join President Trump's Council on Sports, Fitness, and Nutrition.' One athlete and sports star who won't be participating is Eagles' All-Pro running back Saquon Barkley. Following Monday's practice, Barkley disputed the initial press release, stating that he will not be a member of the presidential council. According to the Washington Post, President Trump on Thursday announced that the presidential fitness test, a hallmark of American physical education programs, will be making a comeback in public schools. The assessment was retired and replaced by a fitness program under the Obama administration. The presidential fitness test was initiated in the 1950s by a council established by President Dwight D. Eisenhower that was directed to improve the physical fitness of American youths, in response to fears they were falling behind their European counterparts when it came to athleticism. The project is an alternative way to get anti-obesity drugs to Medicare and Medicaid patients, after the administration said in April that neither program would cover GLP-1s for weight loss. In doing so, it scrapped a 2024 Biden administration proposal for the programs to start covering GLP-1s for patients with obesity. Several high-profile athletes — all of whom have existing ties to Trump — attended the ceremony and will serve on the President's Council on Sports, Fitness and Nutrition. The attendees included professional golfer Bryson DeChambeau, who will chair the council; controversial National Football League kicker Harrison Butker; World Wrestling Entertainment mainstay Paul 'Triple H' Levesque; golfer Annika Sorenstam; and football Hall of Famer Lawrence Taylor. The Eagles running back wasn't in attendance and said he was shocked to hear his name mentioned. The list also includes NFL Commissioner Roger Goodell, whom Trump repeatedly scrutinized during his first presidential term. Barkley was criticized during the off-season for spending time with President Trump on a golf outing prior to the Eagles' ring celebration. This article originally appeared on Eagles Wire: Saquon Barkley is not on President Trump's Council on Sports Nutrition
Yahoo
34 minutes ago
- Yahoo
Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) stock experienced a volatile trading session on Monday, after the company announced positive topline results from its Phase 2 RADIANT study evaluating vormatrigine in patients with focal onset seizures and generalized epilepsy. The stock initially surged on the news, but then reversed course and is currently trading down approximately 9%. The central nervous system (CNS) disorders-focused company said the topline results from the Phase 2 RADIANT study included data from 37 patients.'These findings build on our earlier clinical data showing a differentiated profile for vormatrigine as a fast-acting, no-titration, once-daily oral drug with no requirement to be taken with food, and a favorable DDI profile, all of which are unseen in ASMs currently in the market or in development,' said Marcio Souza, president and CEO of Praxis. In an investor presentation on the company website, Praxis noted that the trial showed a median seizure reduction of around 56.3%, with 60% of the patients achieving at least a 50% reduction in seizures. This positive outcome has encouraged the company to move forward with a Phase 2/3 trial, even though 23% of patients discontinued the study. 54% of patients achieved at least a 50% seizure reduction threshold in Week 1 and 67% in Week 8. In the last month of the dataset, 22% of the patients experienced a 100% reduction in seizure frequency. The company added that most adverse events were mild to moderate and transient. All severe and serious adverse events (AEs) were recovered and resolved. The investor presentation noted that the investigators had the option to reduce the dose of the background medication to manage AEs; when done (6 patients), no discontinuation was observed. The company said it is on track to complete the pivotal, 12-week POWER1 study in the fourth quarter of 2025 and, based on the results from RADIANT, it expects to initiate the POWER2 study shortly. On Monday, the company reported cash and investments of approximately $447 million and maintains a cash runway into 2028. In July, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for Praxis Precision's relutrigine, a sodium channel functional state modulator for pediatric use for SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs). The EMBOLD cohort 2 pivotal trial is on track for topline results in the first half of 2026, with NDA filing to follow. Praxis has recently initiated the EMERALD study investigating relutrigine broadly in DEEs. Price Action: PRAX stock is trading lower by 9.51% to $48.95 at last check Monday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Medscape
36 minutes ago
- Medscape
Three FDA-Approved Obesity Drugs That Aren't GLP-1s
This transcript has been edited for clarity. There are currently three FDA-approved oral medications for the long-term treatment of obesity that are not GLP-1 based. Alli or Xenical (generic name orlistat) was approved by the FDA in 1999. It works by inhibiting intestinal lipase and it reduces absorption of dietary fat by up to 30%. Common side effects are gastrointestinal and include fatty or oily stool, fecal urgency, and incontinence. The average placebo-subtracted weight loss is about 3.8%. Alli is the only FDA-approved medication available over the counter. Qsymia is a combination of phentermine and topiramate and was approved by the FDA in 2012. Phentermine is a sympathomimetic, and topiramate is a neurostabilizer that enhances GABA activity. Clinically, the combination pill enhances satiety, decreases appetite, and reduces binge eating behaviors. Common side effects are paresthesias, altered taste, tachycardia, irritability, hypertension, insomnia, and dry mouth. It is currently one of the most effective oral medications, with an average placebo-subtracted weight loss of 8.6%. Contrave is a combination pill of bupropion and naltrexone and was approved by the FDA in 2014. Bupropion is a norepinephrine and dopamine reuptake inhibitor, and naltrexone is a mu opioid receptor antagonist. Clinically, it decreases appetite and cravings. The common side effects are nausea, vomiting, insomnia, constipation, dry mouth, diarrhea, and dizziness. The average placebo-subtracted weight loss is 4.8%.
